CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

Blood

Volumn 123, Issue 3, 2014, Pages 356-365

  Krupka, Christina ^a,b,c   Kufer, Peter ^d   Kischel, Roman ^d   Zugmaier, Gerhard ^d   Bögeholz, Jan ^a,b   Köhnke, Thomas ^a,b   Lichtenegger, Felix S ^a,b   Schneider, Stephanie ^a   Metzeler, Klaus H ^a   Fiegl, Michael ^a   Spiekermann, Karsten ^a,b,e   Baeuerle, Patrick A ^d   Hiddemann, Wolfgang ^a,b   Riethmüller, Gert ^c   Subklewe, Marion ^a,b,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b German Res Cen for Env Health/Clin Coop Gr Hematopoietic Cell Transplantation (CCG HCT)   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Amgen Research GmbH   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 330; BISPECIFIC ANTIBODY; CD33 ANTIGEN; NUCLEOPHOSMIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; FEEDER CELL; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENE TRANSLOCATION; GENOTYPE; HUMAN; IN VIVO STUDY; KARYOTYPE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; STEM CELL; T CELL CULTURE; T CELL DEPLETION; T LYMPHOCYTE; VERY ELDERLY; COCULTURE; CULTURE TECHNIQUE; IMMUNOLOGY; IMMUNOTHERAPY; KARYOTYPING; METABOLISM; METHODOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; CELL CULTURE TECHNIQUES; COCULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; IMMUNOTHERAPY; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES; TIME FACTORS;

EID: 84897019168     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-523548     Document Type: Article

References (39)

1. Lichtenegger FS, Schnorfeil FM, Hiddemann W, Subklewe M. Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy. 2013;5(1):63-78.
2. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11(1):22-30.
3. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891):974-977.
4. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25(1):181-184.
5. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
6. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26):5185-5187.
7. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110-4116. (Pubitemid 46211316)
8. Hofmann M, Große-Hovest L, Nübling T, et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia. 2012;26(6):1228-1237.
9. Castaigne S, Pautas C, Terré C, et al Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
10. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-4860.
11. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176-182. (Pubitemid 40220577)
12. Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P. Biologic properties of a bispecific singlechain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol. 1997;158(8): 3965-3970. (Pubitemid 127488757)
13. Kufer P, Mack M, Gruber R, Lutterbüse R, Zettl F, Riethmüller G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother. 1997;45(3-4):193-197. (Pubitemid 27521458)
14. Löffler A, Kufer P, Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphomadirected cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098-2103. (Pubitemid 30151651)
15. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013;27(5):1107-1115.
16. Lutterbuese R, Raum T, Kischel R, et al. T cellengaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA. 2010;107(28):12605-12610.
17. Friedrich M, Raum T, Lutterbuese R, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody crossreactive with non-human primate antigens. Mol Cancer Ther. 2012;11(12):2664-2673.
18. van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, Schuringa JJ. Establishing longterm cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol. 2007;35(10):1538-1549. (Pubitemid 47419138)
19. Amsellem S, Pflumio F, Bardinet D, et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat Med. 2003;9(11):1423-1427. (Pubitemid 37466194)
20. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13): 3657-3660.
21. Funayama K, Shimane M, Nomura H, Asano S. An evidence for adhesion-mediated acquisition of acute myeloid leukemic stem cell-like immaturities. Biochem Biophys Res Commun. 2010;392(3):271-276.
22. Yang DT, Greenwood JH, Hartung L, Hill S, Perkins SL, Bahler DW. Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations. Am J Clin Pathol. 2005;124(6):930-936. (Pubitemid 41740194)
23. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD81 memory T-cell subsets in response to antigen or homeostatic cytokines. Blood. 2003; 101(11):4260-4266. (Pubitemid 36857786)
24. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
25. De Propris MS, Raponi S, Diverio D, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10): 1548-1551.
26. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295-1302. (Pubitemid 40170906)
27. Pollard JA, Alonzo TA, Loken M, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705-3711.
28. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16): 3187-3205.
29. Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086-4092. (Pubitemid 41775913)
30. Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013; 27(4): 964-967.
31. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26): 6198-6208.
32. Mayani H, Flores-Figueroa E, Chávez-González A. In vitro biology of human myeloid leukemia. Leuk Res. 2009;33(5):624-637.
33. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/ CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226-6233.
34. Kischel R, Hausmann S, Klinger M, Baeuerle PA, Kufer P. Effector memory T cells make a major contribution to redirected target cell lysis by T cellengaging BiTE antibody MT110 [abstract]. Proc Am Assoc Cancer Res. 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 3252.
35. Benthaus T, Schneider F, Mellert G, et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol. 2008; 143(2):230-239.
36. Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93(12): 4116-4124. (Pubitemid 29279253)
37. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010; 28(4):570-577.
38. Grimwade D, Hills RK, Moorman AV, et al National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
39. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.